NCT03640988 is a NA clinical trial of dermaPACE in Diabetic Foot Ulcer, sponsored by SANUWAVE, Inc..

Who is sponsoring NCT03640988?

NCT03640988 is sponsored by SANUWAVE, Inc..

What drugs are being tested in NCT03640988?

Interventions in NCT03640988: dermaPACE.

What condition does NCT03640988 study?

NCT03640988 studies Diabetic Foot Ulcer.

Is NCT03640988 still recruiting?

NCT03640988 is currently terminated. Last updated 8 November 2021.

Last reviewed 2021-11-08 · How we verify

NCT03640988

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of High Energy Acoustic Shock Wave Therapy on Local Skin Perfusion and DFUs

Terminated NA Last updated 8 November 2021

What this trial tests

NA trial testing dermaPACE in Diabetic Foot Ulcer in 2 participants. Terminated before completion.

Timeline

25 April 2019

Primary endpoint
3 January 2021

3 January 2021

Quick facts

Lead sponsor	SANUWAVE, Inc.
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	25 April 2019
Primary completion	3 January 2021
Estimated completion	3 January 2021
Sites	1 location across United States

Drugs / interventions tested

dermaPACE

Conditions studied

Diabetic Foot Ulcer — all drugs for Diabetic Foot Ulcer →

Sponsor

SANUWAVE, Inc.

Who can join

22 and older, any sex, with Diabetic Foot Ulcer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational, single-arm, on-label study. This clinical study will be conducted at up to 2 sites with a total of 10 subjects per site. All subjects will receive standard of care treatment which includes DFU treatments with the dermaPACE device.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetic Foot Ulcer

Currently open trials in the same condition.

NCT07161830 — Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers · NA · recruiting
NCT07396376 — Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers · Phase 1, PHASE2 · recruiting
NCT07291817 — Intermittent Negative Pressure for Patients With Diabetic Foot Ulcers (INPRESS) Study · NA · recruiting
NCT07209358 — EDX110 Randomized Control Trial for Treatment of DFUs · NA · recruiting
NCT06938685 — Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03640988 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SANUWAVE, Inc.
Last refreshed: 8 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03640988.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing